These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1553895)

  • 1. Bepridil therapy: guidelines for patient selection and monitoring of therapy.
    Singh BN
    Am J Cardiol; 1992 Apr; 69(11):79D-85D. PubMed ID: 1553895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of bepridil on cardiac electrophysiologic properties.
    Prystowsky EN
    Am J Cardiol; 1992 Apr; 69(11):63D-67D. PubMed ID: 1553893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of bepridil determined from clinical trials in chronic stable angina in the United States.
    Singh BN
    Am J Cardiol; 1992 Apr; 69(11):68D-74D. PubMed ID: 1532469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of bepridil: from review of the European data.
    Coumel P
    Am J Cardiol; 1992 Apr; 69(11):75D-78D. PubMed ID: 1553894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.
    Hollingshead LM; Faulds D; Fitton A
    Drugs; 1992 Nov; 44(5):835-57. PubMed ID: 1280569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
    Singh BN; Wadhani N
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
    Eckardt L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bepridil: importance of serum level in treatment surveillance].
    Viallon A; Laporte-Simitsidis S; Pouzet V; Venet C; Tardy B; Zéni F; Bertrand JC
    Presse Med; 2000 Apr; 29(12):645-7. PubMed ID: 10780196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bepridil and torsades de pointes: are the precautions of use respected?].
    Viallon A; Page Y; Lafond P; Guy C; Cusey I; Tardy B; Zeni F; Lapierre B; Bertrand JC
    Therapie; 1994; 49(5):431-4. PubMed ID: 7855758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem. The Bepridil Collaborative Study Group.
    Singh BN
    Am J Cardiol; 1991 Aug; 68(4):306-12. PubMed ID: 1858672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QT interval and drug therapy.
    Drug Ther Bull; 2016 Mar; 54(3):33-6. PubMed ID: 26966121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
    Hohnloser SH
    Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Torsades de pointes with methadone.
    Prescrire Int; 2005 Apr; 14(76):61-2. PubMed ID: 15875343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
    Faber TS; Zehender M; Van de Loo A; Hohnloser S; Just H
    Clin Cardiol; 1994 Apr; 17(4):197-202. PubMed ID: 8187370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bepridil hydrochloride compared with placebo in patients with stable angina pectoris.
    Narahara KA; Singh BN; Karliner JS; Corday SR; Hossack KF
    Am J Cardiol; 1992 Apr; 69(11):37D-42D. PubMed ID: 1553890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of bepridil versus placebo in angina pectoris: treatment and withdrawal studies.
    Shapiro W
    Am J Cardiol; 1992 Apr; 69(11):43D-49D. PubMed ID: 1553891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Torsade de pointes.
    Campens D
    Anesth Analg; 1996 Oct; 83(4):887. PubMed ID: 8831345
    [No Abstract]   [Full Text] [Related]  

  • 20. Torsades de Pointes after Ondansetron Infusion in 2 Patients.
    Lee DY; Trinh T; Roy SK
    Tex Heart Inst J; 2017 Oct; 44(5):366-369. PubMed ID: 29259513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.